Published in BMC Infect Dis on May 20, 2013
Immunogenicity and Safety Study of a GSK Influenza Vaccine Candidate in Adults. | NCT00714285
Vaccination in elite athletes. Sports Med (2014) 1.50
Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom. BMC Infect Dis (2015) 0.94
AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection. Vaccine (2014) 0.89
Evaluating the case for trivalent or quadrivalent influenza vaccines. Hum Vaccin Immunother (2016) 0.78
Influenza. BMJ (2016) 0.75
Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study. Hum Vaccin Immunother (2016) 0.75
Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 31.71
Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol (1999) 11.94
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep (2010) 10.59
Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med (2009) 5.73
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet (2007) 4.84
Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology (1990) 4.71
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (2009) 3.97
Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med (2009) 3.49
GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines (2007) 2.73
Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine (2012) 2.67
Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev (2010) 2.49
Clinical efficacy of cell culture–derived and egg‐derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis (2010) 2.16
The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother (2012) 2.11
Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine (2009) 2.11
Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. Wkly Epidemiol Rec (2010) 2.10
The need for quadrivalent vaccine against seasonal influenza. Vaccine (2010) 1.92
Multiple genotypes of influenza B virus circulated between 1979 and 2003. J Virol (2004) 1.83
AS03(A)-Adjuvanted influenza A (H1N1) 2009 vaccine for adults up to 85 years of age. Clin Infect Dis (2010) 1.80
Influenza--WHO cares. Lancet Infect Dis (2002) 1.75
Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res (2004) 1.66
Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis (2010) 1.60
Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis (2010) 1.53
Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis (2009) 1.47
Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics (2006) 1.38
Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results. Vaccine (2011) 1.38
An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine (2010) 1.32
Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol (2001) 1.32
The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine (2012) 1.24
A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults. Vaccine (2011) 1.19
Antibody responses to influenza B viruses in immunologically unprimed children. Pediatrics (1991) 1.04
Clinical and genetic characterization of severe influenza B-associated diseases during an outbreak in Taiwan. J Clin Virol (2008) 1.02
Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children. Pediatr Infect Dis J (2012) 1.01
Circulation and antigenic drift in human influenza B viruses in SE Asia and Oceania since 2000. Commun Dis Intell Q Rep (2006) 0.99
A rapid immune response to 2009 influenza A(H1N1) vaccines in adults: a randomized, double-blind, controlled trial. J Infect Dis (2010) 0.91
Cross-protection against homologous drift variants of influenza A and B after vaccination with split vaccine. Intervirology (2006) 0.86
Inactivated split-virion seasonal influenza vaccine (Fluarix): a review of its use in the prevention of seasonal influenza in adults and the elderly. Drugs (2010) 0.78
Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet (2007) 4.84
AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis (2013) 1.95
Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. J Infect Dis (2013) 1.70
Challenge of conducting a placebo-controlled randomized efficacy study for influenza vaccine in a season with low attack rate and a mismatched vaccine B strain: a concrete example. BMC Infect Dis (2009) 1.47
Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol (2011) 1.12
A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years. J Infect Dis (2013) 1.06
Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J Infect Dis (2011) 1.04
Efficacy of inactivated split-virus influenza vaccine against culture-confirmed influenza in healthy adults: a prospective, randomized, placebo-controlled trial. J Infect Dis (2009) 1.03
A phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C adeno-associated virus vaccine. AIDS Res Hum Retroviruses (2008) 1.01
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years. BMC Infect Dis (2013) 0.96
New advances in method validation and measurement uncertainty aimed at improving the quality of chemical data. Anal Bioanal Chem (2004) 0.93
Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccines. Influenza Other Respir Viruses (2014) 0.90
A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respir Viruses (2008) 0.89
Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial. J Clin Virol (2011) 0.86
What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? J Clin Psychiatry (2005) 0.86
Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. BMC Infect Dis (2013) 0.85
A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr Infect Dis J (2010) 0.85
Enantiomeric separation of basic compounds using heptakis(2,3-di-O-methyl-6-O-sulfo)-beta-cyclodextrin in combination with potassium camphorsulfonate in nonaqueous capillary electrophoresis: optimization by means of an experimental design. Electrophoresis (2004) 0.84
Using tolerance intervals in pre-study validation of analytical methods to predict in-study results. The fit-for-future-purpose concept. J Chromatogr A (2007) 0.81
A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Hum Vaccin Immunother (2013) 0.81
Lack of erectogenic activity of a novel selective melanocortin-4 receptor agonist in a clinical experimental model. J Clin Pharmacol (2008) 0.78
A phase 1, open-label safety and immunogenicity study of an AS03-adjuvanted trivalent inactivated influenza vaccine in children aged 6 to 35 months. Hum Vaccin Immunother (2014) 0.78
Genetic and antigenic typing of seasonal influenza virus breakthrough cases from a 2008-2009 vaccine efficacy trial. Clin Vaccine Immunol (2013) 0.77
Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age. Pediatr Infect Dis J (2014) 0.77
Acute Exacerbation and Respiratory InfectionS in COPD (AERIS): protocol for a prospective, observational cohort study. BMJ Open (2014) 0.75
Possible Campylobacter jejuni osteomyelitis in a 14-month-old child. Int J Infect Dis (2003) 0.75
Influence of the nature of the electrolyte on the chiral separation of basic compounds in nonaqueous capillary electrophoresis using heptakis(2,3-di-O-methyl-6-O-sulfo)-beta-cyclodextrin. J Chromatogr A (2005) 0.75